• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Idarucizumab for the Reversal of Dabigatran.

作者信息

Gottlieb Michael, Khishfe Basem

机构信息

Department of Emergency Medicine, Rush University Medical Center, Chicago, IL.

Department of Emergency Medicine, Mount Sinai Hospital, Chicago, IL.

出版信息

Ann Emerg Med. 2017 May;69(5):554-558. doi: 10.1016/j.annemergmed.2016.11.025. Epub 2017 Jan 19.

DOI:10.1016/j.annemergmed.2016.11.025
PMID:28110992
Abstract
摘要

相似文献

1
Idarucizumab for the Reversal of Dabigatran.艾达司珠单抗用于达比加群的逆转
Ann Emerg Med. 2017 May;69(5):554-558. doi: 10.1016/j.annemergmed.2016.11.025. Epub 2017 Jan 19.
2
[Goal-directed administration of antidote for reversal of dabigatran anticoagulation].[达比加群抗凝逆转的解毒剂目标导向给药]
Lakartidningen. 2017 Dec 5;114:ESF3.
3
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.达比加群酯逆转剂依达鲁珠单抗在健康男性志愿者中的安全性、耐受性和疗效：一项随机、安慰剂对照、双盲的 1 期临床试验。
Lancet. 2015 Aug 15;386(9994):680-90. doi: 10.1016/S0140-6736(15)60732-2. Epub 2015 Jun 15.
4
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.年龄和肾功能对依达赛珠单抗药代动力学及依达赛珠单抗介导的达比加群抗凝活性逆转作用的影响：一项随机、双盲、交叉1b期研究
Clin Pharmacokinet. 2017 Jan;56(1):41-54. doi: 10.1007/s40262-016-0417-0.
5
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.依达赛珠单抗，一种达比加群的特异性逆转剂：作用机制、药代动力学和药效学以及1期受试者的安全性和有效性。
Am J Med. 2016 Nov;129(11S):S64-S72. doi: 10.1016/j.amjmed.2016.06.007. Epub 2016 Aug 26.
6
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.依达赛珠单抗，一种达比加群的特异性逆转剂：作用机制、药代动力学和药效学，以及在1期受试者中的安全性和有效性。
Am J Emerg Med. 2016 Nov;34(11S):26-32. doi: 10.1016/j.ajem.2016.09.050. Epub 2016 Sep 28.
7
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.一项在健康志愿者中开展的随机研究，旨在调查达比加群的特异性解毒剂艾达司珠单抗的安全性、耐受性和药代动力学。
Thromb Haemost. 2015 May;113(5):943-51. doi: 10.1160/TH14-12-1080. Epub 2015 Mar 19.
8
Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.关注艾达司珠单抗及其逆转达比加群抗凝作用的潜力。
Drug Des Devel Ther. 2016 May 18;10:1683-9. doi: 10.2147/DDDT.S94167. eCollection 2016.
9
Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.达比加群酯拮抗剂依达鲁珠单抗逆转持续出血致死性猪创伤模型的剂量需求。
Thromb Haemost. 2017 Jun 28;117(7):1370-1378. doi: 10.1160/TH16-11-0824. Epub 2017 Apr 20.
10
[Administration of idarucizumab in spontaneous intracerebral hemorrhage under dabigatran-therapy].[达比加群治疗下依达赛珠单抗在自发性脑出血中的应用]
Ideggyogy Sz. 2017 Sep 30;70(9-10):349-353. doi: 10.18071/isz.70.0349.

引用本文的文献

1
Coagulation Tests and Reversal Agents in Patients Treated with Oral Anticoagulants: The Challenging Scenarios of Life-Threatening Bleeding and Unplanned Invasive Procedures.口服抗凝剂治疗患者的凝血试验及逆转剂：危及生命的出血和意外侵入性操作的挑战性情况
J Clin Med. 2024 Apr 23;13(9):2451. doi: 10.3390/jcm13092451.
2
Reversal and resumption of anticoagulants in patients with anticoagulant-associated intracerebral hemorrhage.抗凝相关脑出血患者抗凝剂的逆转与恢复
Eur J Med Res. 2024 Apr 24;29(1):252. doi: 10.1186/s40001-024-01816-5.
3
Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios.
临床实践及复杂情况下接受直接口服抗凝剂治疗患者的管理
J Clin Med. 2023 Sep 13;12(18):5955. doi: 10.3390/jcm12185955.
4
Therapeutic Potential of Seaweed-Derived Laminaran: Attenuation of Clinical Drug Cytotoxicity and Reactive Oxygen Species Scavenging.海藻来源的海带多糖的治疗潜力：减轻临床药物细胞毒性和清除活性氧
Antioxidants (Basel). 2023 Jun 23;12(7):1328. doi: 10.3390/antiox12071328.
5
How I treat pediatric venous thromboembolism in the DOAC era.在新型口服抗凝药物时代，我如何治疗儿童静脉血栓栓塞症。
Blood. 2024 Feb 1;143(5):389-403. doi: 10.1182/blood.2022018966.
6
Anticoagulation for Atrial Fibrillation in Patients with Decompensated Liver Cirrhosis: Bold and Brave?失代偿期肝硬化患者心房颤动的抗凝治疗：大胆且勇敢？
Diagnostics (Basel). 2023 Mar 18;13(6):1160. doi: 10.3390/diagnostics13061160.
7
Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma.艾达西珠单抗用于达比加群逆转：两例硬膜下血肿患者在急诊科的治疗经验
Trauma Case Rep. 2017 Dec 29;13:46-49. doi: 10.1016/j.tcr.2017.12.003. eCollection 2018 Feb.
8
Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs.直接口服抗凝药物与抗心律失常药物的安全性和相互作用。
Drug Saf. 2017 Nov;40(11):1091-1098. doi: 10.1007/s40264-017-0567-5.
9
Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations.慢性肾脏病患者使用直接口服抗凝剂：患者选择及特殊考量
Int J Nephrol Renovasc Dis. 2017 Jun 12;10:135-143. doi: 10.2147/IJNRD.S105771. eCollection 2017.